|
General Information
|
|
|
Product
|
Von Hippel Lindau Peptide
|
|
Description
|
Antigenic Blocking Peptide Von Hippel-Lindau disease tumor suppressor Antibody
|
|
Verified Applications
|
Immunodepletion, Immunocompetition
|
|
Peptide Description
|
Synthetic peptide taken within amino acid region 130-200 on human Von Hippel-Lindau disease tumor suppressor protein.
|
|
Physical Properties
|
|
|
Quantity
|
250 µg
|
|
Volume
|
100 µl
|
|
Form
|
Antigenic Blocking Peptide
|
|
Purification Method
|
Immobilized antigen affinity chromatography
|
|
Storage
|
-20⁰C for long term storage
|
|
Application Protocol
|
|
Competition/Depletion assay
|
Refer to competition assay protocol
|
|
Protein
|
|
Uniprot #
|
P40337
|
|
Overview
|
Involved in the ubiquitination and subsequent proteasomal degradation via the von Hippel-Lindau ubiquitination complex. Seems to act as a target recruitment subunit in the E3 ubiquitin ligase complex and recruits hydroxylated hypoxia-inducible factor (HIF) under normoxic conditions. Involved in transcriptional repression through interaction with HIF1A, HIF1AN and histone deacetylases. Ubiquitinates, in an oxygen-responsive manner, ADRB2.
|
|
Molecular Function
|
Enzyme binding, Transcription factor binding, Ubiquitin protein ligase activity,
|
|
Subcellular Location
|
Cytoplasm, Peripheral membrane protein, nucleus
|
|
Expression
|
Expressed in the adult and fetal brain and kidney.
|
|
Structure
|
Belongs to the VHL family.
|
|
Alternative Nomenclature
|
Elongin binding protein antibody
G7 protein antibody
HRCA 1 antibody
Protein G7 antibody
pVHL antibody
RCA 1 antibody
VHL 1 antibody
VHLH antibody
Von Hippel Lindau disease tumor suppressor antibody
von Hippel Lindau syndrome antibody
von Hippel Lindau tumor suppressor antibody
Von Hippel Lindau tumor suppressor, E3 ubiquitin protein ligase antibody
|
|
|
|
Von Hippel Lindau Antibody
Von Hippel Lindau Antibody BIOTIN
Von Hippel Lindau Antibody FITC
Von Hippel Lindau Positive Control
